查詢結果分析
相關文獻
- The Effenct of Glimepiride on Glycemic Control and Fasting Insulin Levels
- 類胰高血糖激素胜肽-1(GLP-1)類似物--血糖及體重管理新策
- The Use of Prophylactic Intravenous Immunoglobulin Therapy in Very Low Birthweight Infants
- 極低出生體重早產兒造成腦性麻痺的危險因子之探討
- Comparison of the Outcome of Extremely-Low-Birth-Weight Infants between Two Periods
- Home Oxygen Therapy for Chronic Lung Disease in Very Low-Birth-Weight Infants
- 大專學生體重控制教學設計
- 生長鵝之生長性狀及血液成分變化
- Staphylococcus capitis Bacteremia of Very Low Birth Weight Premature Infants at Neonatal Intensive Care Units: Clinical Significance and Antimicrobial Susceptibility
- Influence of Perinatal Factors on Limit of Viability in Extremely Low Birth Weight Infants
頁籤選單縮合
題 名 | The Effenct of Glimepiride on Glycemic Control and Fasting Insulin Levels=Glimepiride對血糖控制和空腹胰島素濃度之影響 |
---|---|
作 者 | 施婷婷; 李少白; 陳華芬; 李欣宇; | 書刊名 | 藥物食品分析 |
卷 期 | 11:1 2003.03[民92.03] |
頁 次 | 頁1-3+73 |
分類號 | 418.271 |
關鍵詞 | 空腹胰島素濃度; 體重; 血糖控制; Glimepiride; Fasting insulin level; Body weight; Glycemic control; |
語 文 | 英文(English) |
中文摘要 | Glimepiride是一新型的每日服用一次的磺基尿素。動物實驗證實了glimeperide部分的降血糖作用是經由胰臟以外的機轉。本研究目的在於觀察glimepiride對血糖、體重和空腹胰島素濃度的影響。本研究收集了32位第2型糖尿病病患,這些病患無法以飲食、運動來使血糖達到滿意的程度。患者接受12遇之glimepiride治療。他們於第2遇、第4遇、第8週及第12週至門診追蹤。於每次門診,患者的空腹、飯後2小時血糖及體重皆作記錄。於第一次及最後一次門診測定他們的糖化血色素及空腹咦島素濃度。接受Glimepiride治療後患者的空腹、飯後2小時血糖和糖化血色素皆呈現有意義的減少。平均空腹血糖值從237 ± 66.58mg/dL降至149 ± 41.31 mg/dL (p≦ 0.001) ,飯後血糖值從352 ± 112.44 mg/dL降至159 ± 22.86 mg/dL (p≦ 0.001),糖化血色素從11.04 ± 2.91 %降至6.98 ± 1.52% ( p≦ 0.001)。另一方面,空腹胰島素濃度以及體重並沒有統計上有意義的改變。平均空腹胰島素濃度從13.19 ± 1.52μIU/mL增加至16.76 ± 9.48 μIU/mL (p = 0.594) ,平均體重從65.01 ± 8.94 kg增加至68.25 ± 9.80 kg (p = 0.023)。這結果顯示glimepiride的降血糖作用不只是在於刺激胰島素的分泌,也改善胰島素於周邊組織的作用,並可避免太高的血中胰島素濃度。高胰島素血症會導致肥胖、增加低血糖及血管硬化的機率。 |
英文摘要 | Glimepiride is a new once-daily sulfonylurea. Animal studies have shown that it lowers blood glucose through extrapancreatic process. The aim of our study is to observe the effect of glimepiride on glycemic control, body weight change and insulin levels during fasting. Thirty two Type 2 diabetic patients, whose blood glucose levels cannot be controlled adequately with diet and exercise alone, received a 12-week course of glimepiride treatment. They were followed up after 2 weeks, 4 weeks, 8 weeks and 12 weeks. Their fasting, two-hour postprandial blood glucose and body weight were recorded during each visit. Hemoglobulin A1c (HbA1c) and fasting insulin levels were measured at the beginning and end of the study. Fasting plasma glucose (FPG), two-hour postprandial plasma glucose (PPG) and HbA1c values decreased significantly after treatment. The paired mean FPG decreased from 237 ± 66.58 mg/dL to 149 ± 41.31 mg/dL (P ≤0.001), PPG from 352 ± 112.44 mg/dL to 159 ± 22.86 mg/dL (P ≤0.001) and HbA1c from 11.04 ± 2.91% to 6.98 ± 1.52% (P ≤0.001). In contrast, fasting insulin levels and body weight did not have meaningful differences at 0 week and 12 weeks. The paired mean fasting insulin level increased from 13.19 ± 1.52 μIU/mL to 16.76 ± 9.48 μIU/mL (P = 0.594). The paired mean body weight increased from 65.01 ± 8.94 kg at baseline to 68.25 ± 9.80 kg at endpoint (P = 0.023). Glimepiride lowers blood glucose effectively without much effect on fasting insulin levels and body weight gain. These results suggested that glimepiride lowers blood glucose not only by stimulating insulin secretion but also by its extrapancreatic effects. This metabolic effect is desirable because hyperinsulinemia increases body weight, atherosclerosis and risk of hypoglycemia in diabetic patients. |
本系統中英文摘要資訊取自各篇刊載內容。